Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patientsReportar como inadecuado

Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 14:792

Clinical oncology


BackgroundCancer patients undergo routine computed-tomography CT scans and, therefore, iodinated contrast media ICM administration. It is not known whether a time-dependent correlation exists between chemotherapy administration, contrast enhanced CT and onset of acute ICM-related adverse reactions ARs.

MethodsAll consecutive contrast-enhanced CTs performed from 1 January 2010 to 31 December 2012 within 30 days of the last chemotherapy administration were retrospectively reviewed. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. We analyzed time to CT evaluation calculated as the time elapsed from the date of the CT performed to the date of the last chemotherapy administration. Patients were classified into 4 groups based on the antineoplastic treatment: platinum-based, taxane-based, platinum plus taxane and other group.

ResultsOut of 10,472 contrast-enhanced CTs performed, 3,945 carried out on 1,878 patients were considered for the study. Forty acute ICM-related ARs 1.01%; 95% CI, 0.70-1.33 were reported. No differences were seen among immediate within 10 days of the last chemotherapy administration, early 11–20 days and delayed 21–30 days CTs. Median time to CT in patients who experienced an acute ICM-related AR by treatment group was not statistically different: 20 days range 6–30, 17 days range 5–22, 13 days range 8–17, 13 days range 2–29 for the platinum, taxane, platinum plus taxane and other group, respectively P =0.251.

ConclusionsOur results did not reveal any correlation between time to CT and risk of acute ICM-related ARs in cancer patients.

KeywordsIodinated contrast media Time to adverse reaction Hypersensitivity Contrast-enhanced CT Cancer patients and chemotherapy Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-14-792 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Alberto Farolfi - Elisa Carretta - Corradina Della Luna - Angela Ragazzini - Nicola Gentili - Carla Casadei - Domenico Bar


Documentos relacionados